zanubrutinibs

Zanubrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that plays a crucial role in B-cell receptor (BCR) signaling. It is primarily used in the treatment of chronic lymphocytic leukemia (CLL), a type of cancer that affects the B cells in the immune system. Zanubrutinib works by inhibiting BTK, which leads to the inhibition of BCR signaling and subsequent apoptosis (programmed cell death) of CLL cells.

The drug was approved by the U.S. Food and Drug Administration (FDA) in 2021 for the treatment of adult patients with relapsed or refractory CLL who have received at least one prior BTK inhibitor. It is administered orally and has been shown to be effective in improving overall survival and reducing the risk of disease progression in patients with CLL.

Zanubrutinib is generally well-tolerated, with the most common side effects being diarrhea, nausea, and fatigue. However, like all medications, it can cause serious side effects, including an increased risk of infections and bleeding. Therefore, it is important for patients to discuss the potential risks and benefits of zanubrutinib with their healthcare provider before starting treatment.

Clinical trials and real-world data have demonstrated the efficacy and safety of zanubrutinib in the treatment of CLL. Ongoing research is focused on further exploring its potential applications in other types of cancer and immune-related disorders.